Evidence map›Paper›PMID 35163539›Full record

ReviewInternational journal of molecular sciences2022

Phytomedicines to Target Hepatitis B Virus DNA Replication: Current Limitations and Future Approaches.

Rahila Zannat Sadiea, Shahnaj Sultana, Bijan Mohon Chaki, Tasnim Islam, Sharmy Dash, Sharmin Akter, Md Sayeedul Islam, Taheruzzaman Kazi, Abir Nagata, Rocco Spagnuolo and 2 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 4 countries.

Rahila Zannat SadieaDepartment of Microbiology and Hygiene, Bangladesh Agricultural University, Mymensingh 2202, Bangladesh.
Shahnaj SultanaDepartment of Microbiology and Hygiene, Bangladesh Agricultural University, Mymensingh 2202, Bangladesh.
Bijan Mohon ChakiDepartment of Chemistry (Organic Chemistry Division), Begum Rokeya University, Rangpur 5400, Bangladesh.
Tasnim IslamDepartment of Microbiology and Hygiene, Bangladesh Agricultural University, Mymensingh 2202, Bangladesh.
Sharmy DashDepartment of Pharmacology, Bangladesh Agricultural University, Mymensingh 2202, Bangladesh.ORCID 0000-0003-0343-6443
Sharmin AkterDepartment of Physiology, Bangladesh Agricultural University, Mymensingh 2202, Bangladesh.
Md Sayeedul IslamDepartment of Biological Sciences, Graduate School of Science, Osaka University, Osaka 560-0043, Japan.
Taheruzzaman KaziDepartment of Regenerative Dermatology, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan.
Abir NagataDepartment of Regenerative Dermatology, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan.ORCID 0000-0002-6151-5732
Rocco SpagnuoloExperimental and Clinical Medicine Department, Magna Graecia University, 88100 Catanzaro, Italy.ORCID 0000-0002-0871-4644
Rosellina Margherita MancinaDepartment of Molecular and Clinical Medicine, Göteborgs Universitet, 413 45 Gothenburg, Sweden.ORCID 0000-0002-1126-3071
Md Golzar HossainDepartment of Microbiology and Hygiene, Bangladesh Agricultural University, Mymensingh 2202, Bangladesh.ORCID 0000-0002-1487-5444
Bangladesh Agricultural University · BDThe University of Osaka · JPBegum Rokeya University · BDMagna Graecia University · ITUniversity of Gothenburg · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis B virus infection (HBV) is one of the most common causes of hepatitis, and may lead to cirrhosis or hepatocellular carcinoma. According to the World Health Organization (WHO), approximately 296 million people worldwide are carriers of the hepatitis B virus. Various nucleos(t)ide analogs, which specifically suppress viral replication, are the main treatment agents for HBV infection. However, the development of drug-resistant HBV strains due to viral genomic mutations in genes encoding the polymerase protein is a major obstacle to HBV treatment. In addition, adverse effects can occur in patients treated with nucleos(t)ide analogs. Thus, alternative anti-HBV drugs of plant origin are being investigated as they exhibit excellent safety profiles and have few or no side effects. In this study, phytomedicines/phytochemicals exerting significant inhibitory effects on HBV by interfering with its replication were reviewed based on different compound groups. In addition, the chemical structures of these compounds were developed. This will facilitate their commercial synthesis and further investigation of the molecular mechanisms underlying their effects. The limitations of compounds previously screened for their anti-HBV effect, as well as future approaches to anti-HBV research, have also been discussed.

Indexed as

Antiviral AgentsDrug DevelopmentDrug Resistance, ViralHepatitis BHepatitis B virusHumansMolecular StructureMutationPhytochemicalsVirus ReplicationAntiviral AgentsPhytochemicalsDNA replicationfuture approacheshepatitis B viruslimitationsphytomedicines/phytochemicals

Identifiers

PMID35163539
PMCPMC8836293
OpenAlexW4210322021

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.